AstraZeneca PLC
featured
Some of the names on the move ahead of the open.
» Read More
More
-
*Onglyza fails to show cardiovascular benefit in study. *Positive results might have added $1 bln to peak sales. LONDON, June 19- AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study, disappointing investors who had thought it might demonstrate an edge over rivals.
-
LONDON, June 19- AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study.
-
Some scientists to move to Cambridge before 2016. LONDON, June 18- Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay off, its chief executive said on Tuesday.
-
LONDON, June 18- AstraZeneca has chosen a science park on the southern outskirts of Cambridge, England, next to the world-renowned Addenbrooke's Hospital, for its new $500 million global headquarters and research centre.
-
LONDON, June 18- AstraZeneca has chosen a science park in Cambridge, England, next to the world-renowned Addenbrooke's Hospital, as its new $500 million global headquarters and centre of drug research.
-
NEW YORK, June 10- U.S. stocks edged higher in a volatile session on Monday after Standard& Poor's raised its credit outlook for the United States, but uncertainty about when or if the Federal Reserve might reduce its stimulus efforts limited gains.
-
*McDonald's gains after May sales rise. NEW YORK, June 10- U.S. stocks were little changed on Monday after rating agency Standard& Poor's raised its credit outlook for the United States, while investors continued to gauge if and when the Federal Reserve might slow its stimulus efforts.
-
*McDonald's gains after May sales rise. NEW YORK, June 10- Wall Street was poised to open higher after rating agency Standard& Poor's revised its U.S. credit outlook higher and as last week's employment report eased investor jitters that the Federal Reserve could slow the pace of its stimulus efforts in the very near-term.
-
NEW YORK, June 10- U.S. stock index futures were higher on Monday after data showed Japan's economy gained momentum, while last week's employment report eased investor jitters that the Federal Reserve could slow the pace of its stimulus efforts in the very near-term.
-
AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion, as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.
-
*Purchase takes AstraZeneca into emerging LABA/LAMA market. LONDON, June 10- AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.
-
LONDON, June 10- AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.
-
*Key data on new Sanofi products at ADA meeting this month. FRANKFURT, June 7- In a leafy suburb of Frankfurt, a state-of-the-art plant churns out up to 1 million insulin pens every day in French drugmaker Sanofi's drive to keep its no. 2 spot in the $43 billion- a-year diabetes market.
-
HERZLIYA, Israel, June 6- Inspired by its success in high-tech electronics and software, Israel is hoping to pull off the same trick in life sciences. High-tech has been one of Israel's main growth engines and companies such as Intel Inc, IBM and Google Inc have major R&D centres in the country.
-
*AstraZeneca to take $140 million impairment charge in Q2. LONDON, June 4- AstraZeneca is ending development of a rheumatoid arthritis pill that was one of its few late-stage experimental medicines, following disappointing overall results.
-
*AstraZeneca to take $140 mln impairment charge in Q2. LONDON, June 4- AstraZeneca has decided to end development of fostamatinib, a rheumatoid arthritis pill that was one of its few late-stage experimental medicines, following disappointing overall results.
-
LONDON, June 4- AstraZeneca has decided to end development of fostamatinib, a rheumatoid arthritis pill that was one of its few late-stage experimental medicines, following disappointing overall results.
-
LONDON, May 30- Britain's healthcare cost watchdog NICE is recommending a new diabetes drug from Bristol-Myers Squibb and AstraZeneca in some circumstances, marking a change of tack following an earlier blanket rejection.
Most Popular Video
The Fast Money traders share their final trades of the day.
Tuesday, 18 Jun 2013 | 5:00 PM ETAhead of the Fed meeting, the S&P 500 appears headed toward 1,687, StockMonster's Guy Adami says.
Tuesday, 18 Jun 2013 | 6:40 PM ETYou say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.